JP2010509369A5 - - Google Patents

Download PDF

Info

Publication number
JP2010509369A5
JP2010509369A5 JP2009536520A JP2009536520A JP2010509369A5 JP 2010509369 A5 JP2010509369 A5 JP 2010509369A5 JP 2009536520 A JP2009536520 A JP 2009536520A JP 2009536520 A JP2009536520 A JP 2009536520A JP 2010509369 A5 JP2010509369 A5 JP 2010509369A5
Authority
JP
Japan
Prior art keywords
composition
vegf
antibody
use according
average thickness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009536520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509369A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/084320 external-priority patent/WO2008063932A2/en
Publication of JP2010509369A publication Critical patent/JP2010509369A/ja
Publication of JP2010509369A5 publication Critical patent/JP2010509369A5/ja
Pending legal-status Critical Current

Links

JP2009536520A 2006-11-10 2007-11-09 加齢黄斑変性症を処置するための方法 Pending JP2010509369A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86538006P 2006-11-10 2006-11-10
PCT/US2007/084320 WO2008063932A2 (en) 2006-11-10 2007-11-09 Method for treating age-related macular degeneration

Publications (2)

Publication Number Publication Date
JP2010509369A JP2010509369A (ja) 2010-03-25
JP2010509369A5 true JP2010509369A5 (enExample) 2010-12-02

Family

ID=39323041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009536520A Pending JP2010509369A (ja) 2006-11-10 2007-11-09 加齢黄斑変性症を処置するための方法

Country Status (6)

Country Link
US (2) US20100111963A1 (enExample)
EP (1) EP2089059A2 (enExample)
JP (1) JP2010509369A (enExample)
AU (1) AU2007323925A1 (enExample)
CA (1) CA2666709A1 (enExample)
WO (1) WO2008063932A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (pt) * 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
JP5606438B2 (ja) 2008-07-23 2014-10-15 エフ．ホフマン−ラ ロシュ アーゲー 抗血管新生療法を受容可能な被験体の同定
ES2468827T3 (es) * 2010-01-14 2014-06-17 Sanwa Kagaku Kenkyusho Co., Ltd Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
KR20140008303A (ko) * 2010-10-27 2014-01-21 노파르티스 아게 안구 혈관 질환의 치료를 위한 투여 요법
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
WO2012105610A1 (ja) * 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
BR112015003658B1 (pt) * 2012-08-21 2022-09-27 Opko Pharmaceuticals, Llc Formulação oftálmica, uso da dita formulação no tratamento de doença oftálmica do segmento posterior, formulação de lipossomas e suspensão oftálmica lipossomal
JP6470740B2 (ja) * 2013-06-07 2019-02-13 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム
WO2015052104A1 (en) * 2013-10-08 2015-04-16 F. Hoffmann-La Roche Ag Use of n-(4-tert-butylbenzyl)-3-chloro-n-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro- 5-trifluoromethyl-benzamide for the treatment of eye diseases
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US20180280414A1 (en) * 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
KR101880670B1 (ko) * 2015-11-06 2018-08-16 주식회사 모다이노칩 압력 센서를 구비하는 전자기기
KR20210157427A (ko) 2015-12-03 2021-12-28 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
EP3515536A1 (en) * 2016-09-19 2019-07-31 Lupin Limited In-line filter for protein/peptide drug administration
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
MX2020007948A (es) 2018-02-02 2020-12-10 Univ Kyoto Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular.
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US190317A (en) * 1877-05-01 Improvement in barbers chairs
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
MXPA04007583A (es) * 2002-02-11 2005-04-25 Genentech Inc Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno.

Similar Documents

Publication Publication Date Title
JP2022031772A5 (enExample)
JP2015528454A5 (enExample)
JP2017534638A5 (enExample)
NZ596663A (en) Use of vegf antagonists in intraocular neovascular disease treatment
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
JP2017528483A5 (enExample)
RU2017120437A (ru) Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r
JP2014517050A5 (enExample)
Rotenberg et al. Redefining the timing of surgery for obstructive sleep apnea in anatomically favorable patients
CN106999511A (zh) 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
WO2017031319A1 (en) Noradrenergic drug treatment of obstructive sleep apnea
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
WO2008049842A3 (en) Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders
TW202619747A (zh) 藉由投予il-33拮抗劑治療或預防哮喘之方法
JP2012502103A5 (enExample)
JP2015522077A5 (enExample)
JP2022041802A5 (enExample)
JP2012522788A5 (enExample)
JP2018530574A5 (enExample)
JP2024503727A5 (enExample)
Custodio et al. Lack of clinically relevant effect of bictegravir (BIC, B) on metformin (MET) pharmacokinetics (PK) and pharmacodynamics (PD)
JP2018529766A5 (enExample)
Sockalingam et al. Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study.
JP2019507786A5 (enExample)
JP2014531470A5 (enExample)